Transcriptomic profiling of T47D cells treated with alpelisib, B10, and RLY2608
RNA sequencing was performed to characterize transcriptional responses in human T47D breast cancer cells following treatment with alpelisib, B10, or RLY2608. Vehicle-treated T47D cells served as controls. The study includes three biological replicates per condition.